BMY vs SNY
Bristol Myers Squibb and Sanofi, both Healthcare
Bristol Myers Squibb is the larger company at $110B against $100B. Over the past year BMY returned +34% against -11% for SNY. The RyuScore puts SNY ahead, 55 against 54 out of 100.
| Figure | BMY | SNY |
|---|---|---|
| Last close | $59.11 | $40.07 |
| Market cap | $110B | $100B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 13.0 | n/a |
| Dividend yield | 4.2% | n/a |
| 1-year return | +34% | -11% |
| 5-year return | +14% | +2.8% |
| RyuScoresector-relative, 1–10 | 54/100 | 55/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Bristol Myers Squibb
Revenue of $13B in Q2 2026, net income $3.3B. Its largest reported line is Eliquis, 33% of the disclosed total.
Sanofi
Revenue of $24B in H2 2025, net income $2.0B.
Open these two in the interactive comparison to add more names, change the period or see the correlation.